Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Subroto Kundu

Neurology Cleveland, TN Medical Doctor

NPI 1063426302 CMS profile 275593

3555 Keith St Nw, Suite 211, Cleveland, TN 37312

Open in the dashboard

General payments

$17,433

631 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Subroto Kundu of Cleveland, TN is reported in the CMS Open Payments database as having received $17,433 across 631 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,153 36
2024 General $1,161 39
2023 General $983 57
2022 General $2,752 136
2021 General $2,898 134
2020 General $1,804 104
2019 General $6,682 125

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Subroto Kundu
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Subroto Kundu were reported at $1,153. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Subroto Kundu Neurology median Middle half National median
2019 $6,682 $474 $118–$2,177 $163
2020 $1,804 $367 $82–$2,309 $114
2021 $2,898 $438 $104–$2,547 $132
2022 $2,752 $442 $103–$2,388 $149
2023 $983 $464 $119–$2,312 $160
2024 $1,161 $468 $119–$2,323 $164
2025 $1,153 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $4,651 26 payments
  2. UCB, Inc. $1,804 103 payments
  3. Genzyme Corporation $855 35 payments
  4. Sunovion Pharmaceuticals Inc. $757 72 payments
  5. SK Life Science, Inc. $623 33 payments
  6. Eisai Inc. $611 35 payments
  7. Lilly USA, LLC $610 20 payments
  8. Celgene Corporation $603 36 payments
  9. AbbVie, Inc. $551 16 payments
  10. E.R. Squibb & Sons, L.L.C. $451 16 payments
  11. Other $5,917 239 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,284 622 payments
  2. Consulting Fee $3,672 1 payment
  3. Travel and Lodging $411 3 payments
  4. Education $67 5 payments
Products named General payments · program years 2019–2025
  1. AIMOVIG $4,650 21 payments
  2. ZEPOSIA $1,054 52 payments
  3. APTIOM $814 74 payments
  4. Epidiolex $731 20 payments
  5. Briviact $725 40 payments
  6. Vimpat $709 49 payments
  7. Fycompa $534 31 payments
  8. AUBAGIO $516 24 payments
  9. UBRELVY $479 12 payments
  10. NUEDEXTA $350 14 payments
  11. Other $6,047 260 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

2,416

Median for Neurology: 833

Drug cost

$422,423

Median for Neurology: $202,670

Branded share of claims

28.3%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Avonex Pen (4 Pack) Interferon Beta-1a Brand 12 $99,984
Aptiom Eslicarbazepine Acetate Brand 65 $81,579
Briviact Brivaracetam Brand 48 $70,001
Fycompa Perampanel Brand 45 $53,644
Lacosamide Generic 293 $44,778
Nuedexta Dextromethorphan Hbr/Quinidine Brand 12 $18,989
Neupro Rotigotine Brand 11 $10,806
Levetiracetam Generic 433 $8,974
Valtoco Diazepam Brand 11 $8,180
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 236 $4,514

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$32,916

Medicare's payments for the services billed

Medicare patients

176

Average age 68

Services billed

405

89 women, 87 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 47%
Depression 34%
Diabetes 23%
Ischemic heart disease 20%
COPD 20%
Atrial fibrillation 19%
Alzheimer's or dementia 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISUNLA
  • Lilly USA, LLC $153
$153 — —
ZEPOSIA
  • Celgene Corporation $116
$116 — —
Briviact
  • UCB, Inc. $112
$112 48 —
VYVGART Hytrulo
  • ARGENX US, INC. $101
$101 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $98
$98 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

631 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record